DJE Kapital AG Buys New Holdings in Eli Lilly and Company $LLY

DJE Kapital AG purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 257,897 shares of the company’s stock, valued at approximately $234,543,000. Eli Lilly and Company makes up approximately 5.2% of DJE Kapital AG’s holdings, making the stock its 4th largest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Spire Wealth Management increased its holdings in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after purchasing an additional 592 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Iams Wealth Management LLC bought a new position in Eli Lilly and Company during the fourth quarter worth about $754,000. May Hill Capital LLC boosted its holdings in Eli Lilly and Company by 131.6% during the fourth quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after buying an additional 1,801 shares during the last quarter. Finally, Caisse Des Depots ET Consignations grew its position in shares of Eli Lilly and Company by 17.3% during the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock worth $11,643,000 after buying an additional 1,600 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.7%

NYSE LLY opened at $1,146.90 on Tuesday. The firm has a market cap of $1.08 trillion, a P/E ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s 50-day moving average is $1,122.49 and its 200-day moving average is $1,036.98. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Wolfe Research restated an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Barclays upped their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Finally, Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.